HC Wainwright Forecasts Pharvaris FY2030 Earnings

Pharvaris N.V. (NASDAQ:PHVS) – HC Wainwright issued their FY2030 EPS estimates for shares of Pharvaris in a research note issued on Monday, April 6th. HC Wainwright analyst P. Trucchio expects that the company will earn $5.37 per share for the year. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

A number of other analysts also recently commented on PHVS. Wedbush increased their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Royal Bank Of Canada cut their price target on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.80.

Pharvaris Trading Down 1.9%

PHVS stock opened at $27.84 on Tuesday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -8.26 and a beta of -2.58. Pharvaris has a 12 month low of $11.51 and a 12 month high of $29.85. The firm has a 50-day moving average of $27.08 and a two-hundred day moving average of $25.48.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $75,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Pharvaris during the 4th quarter worth approximately $86,000.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wedbush raised its price target to $42 and kept an “outperform” rating, implying roughly a 50% upside from current levels — a near-term bullish catalyst from an influential equity shop. Benzinga
• Positive Sentiment: HC Wainwright issued long-range FY2030 estimates calling for EPS of $5.37 and maintains a “Buy” rating with a $60 target — a highly constructive, bullish long-term projection that signals analysts expect strong eventual profitability. MarketBeat
• Neutral Sentiment: Brokerage consensus remains favorable overall — PHVS is reported to have an average rating of “Moderate Buy,” reflecting broad analyst support but varied views on timing and magnitude of upside. American Banking News
• Neutral Sentiment: Royal Bank of Canada trimmed its price target slightly from $52 to $51 but left an “outperform” rating in place — a small downgrade in projection that still implies large upside, so its market impact is muted. Benzinga
• Negative Sentiment: Coverage and commentary are questioning whether Phase 3 completion and projected 2025 losses change Pharvaris’ investment narrative; concerns about near-term profitability and how the market will value post‑Phase 3 commercialization are weighing on sentiment. Yahoo Finance

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.